Q: What is Spinraza used for?

Spinraza is used to treat spinal muscular atrophy .

Q: How does Spinraza work?

Targeting the SMN Protein Spinal muscular atrophy (SMA) is caused by a deficiency of survival motor neuron (SMN) protein. This protein is essential for the health of motor neurons, which are the nerve cells in the spinal cord that control muscle movement. When these protein levels are too low, motor neurons can become damaged or die, leading to muscle weakness and wasting. The Role of the SMN2 Gene Humans have a backup gene called SMN2 that can also produce the SMN protein. However, in most people, the SMN2 gene contains a splicing error that causes it to produce mostly non-functional, shortened protein. Only a small fraction of the protein made by this backup gene is useful to the body. How Spinraza Works Spinraza is an antisense oligonucleotide, which is a short string of synthetic genetic material. It is designed to bind to the messenger RNA (mRNA) produced by the SMN2 gene. By binding to a specific spot, it corrects the splicing error, allowing the SMN2 gene to produce more full-length, functional SMN protein. By increasing the amount of functional protein available to the central nervous system, Spinraza helps to: Support nerve health: It helps maintain the motor neurons that are necessary for muscle function. Preserve muscle function: By protecting the nerves, the medicine aims to slow the progression of muscle weakness and improve motor milestones.

Q: What are the active ingredients in Spinraza?

The active ingredient in Spinraza is nusinersen .

Q: What are the side effects of Spinraza?

Common side effects of Spinraza may include: Headache Back pain Vomiting Always consult with a healthcare professional about potential side effects.

Q: What drug class is Spinraza?

Spinraza belongs to the antisense oligonucleotide drug class.

Q: What is the dosage of Spinraza and how do I take it?

Administration Method Spinraza is administered as an intrathecal injection, which involves injecting the medication directly into the fluid surrounding the spinal cord. This procedure, known as a lumbar puncture, must be performed by a healthcare professional experienced in this technique. Before the procedure, healthcare providers may use imaging guidance, such as ultrasound or CT scans, to assist with the injection. Sedation may be considered for some patients to help them remain still during the administration. Dosing Schedule The treatment schedule for Spinraza is divided into two phases: Loading Doses: The initial treatment consists of four doses. The first three doses are given at two-week intervals. The fourth dose is administered one month after the third dose. Maintenance Doses: After the loading phase, maintenance doses are administered once every four months. Missed Doses If a scheduled dose is missed, it should be administered as soon as possible. The healthcare provider will then adjust the schedule for future doses to ensure the appropriate time remains between injections.

Q: Is Spinraza safe during pregnancy and breastfeeding?

Pregnancy There are no adequate or well-controlled studies on the use of Spinraza in pregnant women. In animal studies involving mice and rabbits, no evidence of harm to the fetus or birth defects was observed, even at doses higher than those typically used in humans. However, animal research does not always predict how a drug will affect human pregnancy. If you are pregnant or planning to become pregnant, it is important to discuss the potential risks and benefits of treatment with your healthcare provider. They can help determine if the clinical need for the medication outweighs the potential risks to the fetus. Breastfeeding It is not known whether Spinraza passes into human breast milk or if it has any effect on a nursing infant or milk production. In animal studies, the drug was detected in the milk of lactating mice. When considering breastfeeding while on this medication, the developmental and health benefits of breastfeeding should be weighed against the mother's clinical need for the drug and any potential adverse effects on the breastfed child.

Q: What forms and strengths does Spinraza come in?

Available Forms Spinraza is supplied as a preservative-free solution for intrathecal administration. It is provided in the following form: Single-dose vial: A liquid solution intended for a single injection into the space around the spinal cord.

Q: What is the FDA approval status of Spinraza?

FDA Approval and Indication The U.S. Food and Drug Administration (FDA) approved Spinraza on December 23, 2016. It is indicated for the treatment of spinal muscular atrophy (SMA) in both children and adults. Spinraza was the first medication approved by the FDA to treat this rare genetic condition. Regulatory History During its development, Spinraza received several special designations from the FDA to expedite its availability, including: Fast Track: A process designed to facilitate the development and review of drugs for serious conditions with unmet medical needs. Priority Review: An expedited review process for drugs that offer significant improvements in safety or effectiveness. Orphan Drug Designation: A status granted to drugs intended for the treatment of rare diseases. Safety and Monitoring There are currently no Boxed Warnings or Risk Evaluation and Mitigation Strategies (REMS) required for Spinraza. However, the FDA-approved labeling includes warnings regarding the risk of low blood platelet counts (thrombocytopenia) and kidney damage (renal toxicity). Healthcare providers are advised to perform blood and urine tests before starting treatment and before each dose to monitor for these potential issues.

Question 1

What is Spinraza?

Accepted Answer

Spinraza is a type of medicine known as an antisense oligonucleotide. It is designed to address the underlying genetic deficiency of survival motor neuron protein.

By targeting specific genetic sequences, the medication helps the body produce more functional protein to support the health and maintenance of motor neurons.

Question 2

What is Spinraza used for?

Accepted Answer

Spinraza is used to treat spinal muscular atrophy.

Question 3

How does Spinraza work?

Accepted Answer

Targeting the SMN Protein

Spinal muscular atrophy (SMA) is caused by a deficiency of survival motor neuron (SMN) protein. This protein is essential for the health of motor neurons, which are the nerve cells in the spinal cord that control muscle movement. When these protein levels are too low, motor neurons can become damaged or die, leading to muscle weakness and wasting.

The Role of the SMN2 Gene

Humans have a backup gene called SMN2 that can also produce the SMN protein. However, in most people, the SMN2 gene contains a splicing error that causes it to produce mostly non-functional, shortened protein. Only a small fraction of the protein made by this backup gene is useful to the body.

How Spinraza Works

Spinraza is an antisense oligonucleotide, which is a short string of synthetic genetic material. It is designed to bind to the messenger RNA (mRNA) produced by the SMN2 gene. By binding to a specific spot, it corrects the splicing error, allowing the SMN2 gene to produce more full-length, functional SMN protein.

By increasing the amount of functional protein available to the central nervous system, Spinraza helps to:

Support nerve health: It helps maintain the motor neurons that are necessary for muscle function.
Preserve muscle function: By protecting the nerves, the medicine aims to slow the progression of muscle weakness and improve motor milestones.

Question 4

What are the active ingredients in Spinraza?

Accepted Answer

The active ingredient in Spinraza is nusinersen.

Question 5

What are the side effects of Spinraza?

Accepted Answer

Common side effects of Spinraza may include:

Headache
Back pain
Vomiting

Always consult with a healthcare professional about potential side effects.

Question 6

What drug class is Spinraza?

Accepted Answer

Spinraza belongs to the antisense oligonucleotide drug class.

Question 7

What is the dosage of Spinraza and how do I take it?

Accepted Answer

Administration Method

Spinraza is administered as an intrathecal injection, which involves injecting the medication directly into the fluid surrounding the spinal cord. This procedure, known as a lumbar puncture, must be performed by a healthcare professional experienced in this technique.

Before the procedure, healthcare providers may use imaging guidance, such as ultrasound or CT scans, to assist with the injection. Sedation may be considered for some patients to help them remain still during the administration.

Dosing Schedule

The treatment schedule for Spinraza is divided into two phases:

Loading Doses: The initial treatment consists of four doses. The first three doses are given at two-week intervals. The fourth dose is administered one month after the third dose.
Maintenance Doses: After the loading phase, maintenance doses are administered once every four months.

Missed Doses

If a scheduled dose is missed, it should be administered as soon as possible. The healthcare provider will then adjust the schedule for future doses to ensure the appropriate time remains between injections.

Question 8

Is Spinraza safe during pregnancy and breastfeeding?

Accepted Answer

Pregnancy

There are no adequate or well-controlled studies on the use of Spinraza in pregnant women. In animal studies involving mice and rabbits, no evidence of harm to the fetus or birth defects was observed, even at doses higher than those typically used in humans. However, animal research does not always predict how a drug will affect human pregnancy.

If you are pregnant or planning to become pregnant, it is important to discuss the potential risks and benefits of treatment with your healthcare provider. They can help determine if the clinical need for the medication outweighs the potential risks to the fetus.

Breastfeeding

It is not known whether Spinraza passes into human breast milk or if it has any effect on a nursing infant or milk production. In animal studies, the drug was detected in the milk of lactating mice. When considering breastfeeding while on this medication, the developmental and health benefits of breastfeeding should be weighed against the mother's clinical need for the drug and any potential adverse effects on the breastfed child.

Question 9

What forms and strengths does Spinraza come in?

Accepted Answer

Available Forms

Spinraza is supplied as a preservative-free solution for intrathecal administration. It is provided in the following form:

Single-dose vial: A liquid solution intended for a single injection into the space around the spinal cord.

Question 10

What is the FDA approval status of Spinraza?

Accepted Answer

FDA Approval and Indication

The U.S. Food and Drug Administration (FDA) approved Spinraza on December 23, 2016. It is indicated for the treatment of spinal muscular atrophy (SMA) in both children and adults. Spinraza was the first medication approved by the FDA to treat this rare genetic condition.

Regulatory History

During its development, Spinraza received several special designations from the FDA to expedite its availability, including:

Fast Track: A process designed to facilitate the development and review of drugs for serious conditions with unmet medical needs.
Priority Review: An expedited review process for drugs that offer significant improvements in safety or effectiveness.
Orphan Drug Designation: A status granted to drugs intended for the treatment of rare diseases.

Safety and Monitoring

There are currently no Boxed Warnings or Risk Evaluation and Mitigation Strategies (REMS) required for Spinraza. However, the FDA-approved labeling includes warnings regarding the risk of low blood platelet counts (thrombocytopenia) and kidney damage (renal toxicity). Healthcare providers are advised to perform blood and urine tests before starting treatment and before each dose to monitor for these potential issues.

Question 11

What should I know about Spinraza and cost?

Accepted Answer

Factors Affecting Cost

Spinraza is a specialty medication used to treat spinal muscular atrophy (SMA). Because it is administered as an intrathecal injection—meaning it is injected directly into the fluid surrounding the spinal cord—the total cost of treatment typically includes several components:

Medication Price: The cost of the drug itself.
Clinical Administration: Fees for the healthcare professional performing the procedure.
Facility Charges: Costs associated with the hospital or clinic where the injection is performed.
Supportive Care: Potential costs for imaging (such as ultrasound or X-ray) used to guide the needle, or sedation if required.

Insurance and Support

Most insurance plans, including private insurance and government programs like Medicare and Medicaid, provide coverage for Spinraza. However, patients often need to meet specific criteria, and healthcare providers must usually obtain prior authorization from the insurance company before starting treatment.

Financial assistance programs may be available through the manufacturer to help eligible patients with out-of-pocket expenses. Patients and caregivers should consult with their insurance provider and medical team to determine the specific coverage details and explore available support options.

Spinraza

📋Overview

How It Works

Uses

Active Ingredients

Common Side Effects

Warnings & Precautions

Dosage

Pregnancy & Breastfeeding

Frequently Asked Questions

📚References

Found an Error?

Find Discounts for Spinraza

Hospitals.net Disclosure